Agitation is a common Alzheimer’s disease symptom, manifesting as pacing and restlessness as well as verbal and physical aggression to family members and caregivers. The drugs used to quell these ...
The FDA has approved Auvelity as the first non-antipsychotic treatment for agitation in Alzheimer's disease, marking a major ...
Axsome Therapeutics AXSM has been witnessing a strong sales uptake for its lead marketed drug, Auvelity (AXS-05), which is approved for treating major depressive disorder. Since its launch in the ...
Axsome Therapeutics’ AXSM lead drug, Auvelity (AXS-05), approved for treating major depressive disorder, has witnessed strong sales uptake since its approval and launch. Auvelity, the first approved ...
AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer’s disease The safety and tolerability profile of ...
NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host ...
The U.S. Food and Drug Administration has approved the expanded use of Axsome Therapeutics' Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets to treat ...
The U.S. Food and Drug Administration has approved a label expansion for Axsome Therapeutics’ (AXSM) depression therapy Auvelity, allowing its use as a treatment for agitation associated with dementia ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results